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Summary 
Antibody-blocking studies have demonstrated the role of CD6 in thymocyte-thymic epithelial 
(TE) cell adhesion. Here we report that CD6 expressed by COS cells mediates adhesion to TE 
cells and that this interaction is specifically blocked with an anti-CD6 monodonal antibody (mAb) 
or with a mAb 04-81) that recognized a TE cell antigen. We isolated and expressed a cDNA 
clone encoding this antigen and show that COS cells transfected with this cDNA bind a CD6 
immunoglobulin fusion protein (CD6-Rg). This antigen, which we named ALCAM (activated 
leukocyte-cell adhesion molecule) because of its expression on activated leukocytes, appears  to 
be the human homologue of the chicken neural adhesion molecule BEN/SC-1/DM-GRASP. 
The gene was mapped to human chromosome 3q13.1-q13.2  by fluorescence in situ hybridization 
of cDNA probes to metaphase chromosomes. We prepared an ALCAM-Rg fusion protein and 
showed that it binds to COS cell transfectants expressing CD6, demonstrating that AI.CAM 
is a CD6 ligand. The observations that ALCAM is also expressed by activated leukocytes and 
that both ALCAM and CD6 are expressed in the brain suggest that ALCAM-CD6 interactions 
may play a role in the binding of T and B cells to activated leukocytes, as well as in interactions 
between cells of the nervous system. 
C 
D6 is a type I membrane protein (1) expressed by thymo- 
cytes, mature T cells, a subset orb cells known as B-1 
cells, and by some cells in the brain (2-4). CD6 is a member 
of the scavenger receptor cysteine-rich (SRCR) 1 family of 
proteins (5), which includes the type I macrophage scavenger 
receptor (6) and the leukocyte antigens CD5 (7, 8),  M130 
(9), and WC1 (10), among others. The extracellular domain 
of CD6 is composed of three SRCR domains and has the 
same domain organization as CD5. 
Antibody cross-linking studies have shown that CD6 can 
function as an accessory protein in T cell activation (3, 11-15). 
After T cell activation, CD6 becomes hyperphosphorylated 
on Ser and Thr residues (12, 16-18)  and phosphorylated on 
Tyr residues (17). Anti-CD6 mAbs have been used in a clin- 
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ical setting to prevent renal and bone marrow transplant re- 
jection (19, 20). Taken together, these data suggest that the 
interaction of CD6 with its physiological ligand plays a role 
in regulating the function of T  cells in vivo. 
We had previously reported the use of a CD6 immuno- 
globulin fusion protein (CD6-Rg)  to identify a number of 
cell lines that express a CD6 ligand (21, 22). We found that 
both lymphoid and nonlymphoid cell lines, including human 
and murine thymic epithelial (TE) cells, expressed a putative 
CD6 ligand. This observation was consistent with the finding 
that an anti-CD6 mAb was able to partially block thymo- 
cyte-TE cell binding (23).  In an effort to identify the CD6 
ligand, antibodies from the 5th International Workshop on 
Human Leukocyte Differentiation Antigens (November 1993, 
Boston, MA) (24) known to bind to TE cells were screened 
for their ability to block the binding of CD6-Rg to TE cells 
(22). One antibody, J4-81 (25), was found to inhibit this in- 
teraction. Immunoprecipitation studies with CD6-Kg and 
J4-81 showed that these two proteins recognized a glycopro- 
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Volume 181  June 1995  2213-2220 tein of "-100  kD.  Partial  tryptic digestion  of this  protein 
resulted in a similar set of peptide fragments, providing fur- 
ther evidence that J4-81  recognized a  CD6  ligand  (22). 
In this report, we describe the use of CD6-expressing COS 
cells and antibody-blocking studies to show that CD6 can 
mediate adhesion  to TE cells and  that  this interaction can 
be blocked with either the anti-CD6 mAb T12 or the J4-81 
mAb.  In addition, we report on the cloning and character- 
ization of a cDNA that encodes the antigen recognized by 
J4-81 and the chromosomal localization of this gene. We found 
that this protein was also expressed by activated T  cells, B 
cells, and monocytes, and so named it ALCAM, for activated 
leukocyte-cell adhesion molecule. Lastly, using soluble recom- 
binant proteins and COS cell transfectants, we demonstrate 
that  the antigen  recognized by J4-81  is a  CD6  ligand. 
Materials and Methods 
Cell Lines, Tissue Culture, Antibodies.  TE cells were cultured 
by an explant technique as described  (26, 27).  COS cells, breast 
carcinoma HBbl00, B cell lymphoma cell lines Ramos, Raji, and 
Daudi, T cell lymphoma cell lines CEM and MOLT4, erythroleu- 
kemia cell line K562, and monocyte-like cell lines HL60 and U937 
were obtained from American Type Culture CoUection (Rockville, 
MD) and maintained under standard  tissue culture conditions in 
Iscove's modified Dulbecco's medium plus 10% fetal bovine serum. 
The NK-like cell line YT was obtained from E. Podack (University 
of Miami School of Medicine, Miami, FL). Antibodies used in this 
study were J4-81 (25) as ascites, Len4 (anti-CD3)-PE (Becton Dick- 
inson & Co., Mountain View, CA), G3-6 (anti-CD6; J. Ledbetter, 
Bristol-Myers Squibb, Seattle, WA), anti-L6 (Bristol-Myers Squibb), 
T12 (anti-CD6; American Type Culture Collection), and P3 (Amer- 
ican Type Culture Collection). 
Binding of TE Cells to COS Cell Transfectants Expressing CD6 
(COS-CD6).  COS-CD6  and  COS-neo cells were prepared by 
cotransfecting a plasmid encoding CD6 (1) and the pSVneo plasmid 
(28).  After  G418  selection,  CD6 +  cells  were  cloned  using  a 
FACStar p~uS|  (Becton Dickinson & Co.) fluorescence-activated cell 
sorter. COS-neo, COS-CD6, and TE cells were used in a suspen- 
sion binding assay. To differentiate between COS cells and TE cells, 
TE cells were labeled with 1 #M calcein AM (Molecular Probes 
Inc., Eugene, OR) for 15 min at 37~  in PBS before harvest. Cal- 
cein AM-labeled cells are fluorescent and can be differentiated from 
unlabeled cells by fluorescence microscopy.  Adhesion was quanti- 
rated by scoring the percentage of COS-CD6 cells that were con- 
jugated with TE cells. For blocking adhesion, antibodies T12, J4- 
81, and P3 were used at or in excess of saturating binding titers. 
Cloning and Characterization of the Gene for the Antigen Recog- 
nized by mAbJ4-81.  J4-81 immunoaf~nity purification of ALCAM 
from HBL-100 cells (~3  x  10  ~) was performed as described (29). 
The purified protein and CNBr fragments were analyzed in a pulsed- 
liquid protein sequencer by previously described  methods (30). 
NH2-terminal sequences were screened against  the SwissProt  data 
base using Genetics Computer Group (Madison, WI) sequence anal- 
ysis software. Chicken BEN probes were synthesized by PCR from 
a chicken embryo cDNA library (Clontech, Palo Alto, CA), random 
prime labeled with 32p-dCTP, and used to screen a PHA-activated 
human T cell cDNA library.  A partial cDNA clone was isolated; 
200 bp of the 5' end of this cDNA was used  to isolate  a clone 
containing the entire coding region from a HL60 cDNA library. 
Data base searches with the cDNA-derived peptide sequence  of 
ALCAM were performed using the BLAST program; alignments 
and consensus sequence derivation of the four highest scoring hits 
were performed using the Pileup and Pretty programs from the 
Genetics Computer Group sequence  analysis software. 
Northern Blot Analysis.  PBMC were isolated from whole blood 
with lymphocyte separation medium (Organon Teknika, Rockville, 
MD) according to the manufacturer's instructions. PBMC were 
stimulated with 1/~g/ml PHA (Boehringer Mannheim Corp., In- 
dianapolis, IN). Total cellular RNA was prepared with TRIzol re- 
agent (GIBCO BRL, Gaithersburg, MD).  Monocytes were iso- 
lated from PBMC by adherence to plastic for 2.5 h. The RNAs 
were fractionated on a denaturating formaldehyde gel;  25 #g of 
P,  NA was loaded for all samples except for monocytes, where 15 
#g  was  loaded.  RNA  was  transferred  to  nitrocellulose  TC 
(Schleicher & SchueU, Inc., Keene, NH) and probed with a random- 
primed, 32p-dCTP-labeled ALCAM or glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) cDNA. Filters were exposed to film at 
-70~  and developed. 
PHA Blast Preparation, Staining.  PBMC were isolated and acti- 
vated with PHA as described above and stained  on selected days 
with mAb J4-81 (1:200) or CD6-Kg (50 #g/ml) followed by a FITC- 
labeled second antibody and anti-CD3-PE; cytofluorometric anal- 
ysis ofJ4-81 staining T cells was performed on a FACScan  |  (Becton 
Dickinson & Co.) by gating on CD3 + cells. 
Chromosomal  Mapping of the Gene Encoding ALCAM.  Two over- 
lapping cDNA clones of the human ALCAM gene containing 2.2- 
and 1.9-kb inserts in CDM8 were used as probes for fluorescence 
in situ hybridization (FISH) as described (31). The probe was la- 
beled with biotin-dUTP by nick translation and was hybridized 
at a concentration of 500 ng/50 #1 per slide to pretreated and dena- 
tured metaphase chromosomes from a human PHA-stimulated  lym- 
phocyte culture. Salmon sperm DNA served as carrier, but no human 
genomic DNA was used as competitor. After incubation, washing, 
signal detection with avidin-FITC (Vector Laboratories, Inc., Burlin- 
game, CA), and one round of amplification with biotinylated goat 
anti-avidin D antibody (Vector Laboratories,  Inc.), chromosomes 
were counterstained with propidium iodide and analyzed under an 
eph%orescence microscope (Axiophot; Carl Zeiss, Inc., Thomwood, 
NY) as described (31). Hybridization signals were considered specific 
only when the signal was observed on both chromatids of a chro- 
mosome. Results were recorded by digital imaging using a cooled 
charge-coupled device camera and displayed in pseudocolors. 
Binding of CD6-Rg to ALCAM-expressing COS Cells and Binding 
of ALCAM-Rg to CD6-expressing COS Cells.  COS cells were ei- 
ther mock transfected with parent vector CDM8 or with cDNA 
clones encoding CD6 or ALCAM by the DEAE-dextran method 
(32). 3 d after transfection, the cells were detached with PBS/0.5 
mM  EDTA,  washed  with  PBS,  and  resuspended  in  PBS/1% 
BSA/0.1% NaN3 (PBA) containing the following concentrations 
of mAbs or fusion proteins: J4-81  (anti-ALCAM) 1:200 dilution 
of ascites, G3-6 (anti-CD6)  5 /~g/ml,  CD6-Rg  50/~g/ml,  and 
ALCAM-Rg 25 #g/ml.  After 30 min on ice, cells were washed 
twice with PBA and resuspended in PBA containing either goat 
anti-mouse or human IgG-FITC for 30 min on ice. The cells were 
washed twice in PBA, once with PBS, fixed in PBS/1% formalde- 
hyde, and analyzed by flow cytometry. 
Results and Discussion 
CD6  on  Transfected COS  Cells  Promotes  TE  Cell Adhe- 
sion.  To directly examine the role of CD6 in thymocyte-TE 
cell adhesion, we prepared a stable COS cell transfectant ex- 
pressing CD6. COS-CD6 supported TE cell adhesion, while 
2214  Cloning of the CD6 Ligand COS cells transfected  with the parent vector alone (COS- 
neo) did not (Fig. 1). The adhesion of TE cells to COS-CD6 
cells was inhibited by pretreating the COS-CD6 ceils with 
anti-CD6 mAb T12 or by pretreating TE cells with J4-81 
mAb (Fig. 1 B), suggesting that CD6-mediated adhesion to 
TE cells involves the molecule  recognized by mAb J4-81. These 
findings provide further evidence that CD6 plays a role in 
the binding of thymocytes to TE cells and are consistent with 
our previous data showing that pretreating TE cells with J4- 
81 blocks their ability to bind CD6-Rg (22). 
Cloning and Characterization  of the Antigen Recognized by 
mAbJ4-81 (ALCAM).  A J4-81  affinity column was used 
to purify the protein from HBL-100, a breast carcinoma cell 
line that expressed high levels of a CD6 ligand (21) and the 
antigen recognized by J4-81 (22). Amino acid sequences ob- 
tained from intact protein and internal peptide fragments were 
found to have substantial homology with the chicken neural 
adhesion molecule BEN/SC-1/DM-GRASP (33-35), which 
was also reported to be expressed by activated chicken leuko- 
cytes (36). DNA fragments corresponding to chicken BEN 
were obtained by PCR and used to screen a PHA-activated 
human T cell cDNA library. A single clone that did not con- 
tain the complete coding region was isolated. A 200-bp PCR 
fragment derived from the 5' region of this clone was used 
to isolate an •l.9-kb  cDNA clone that contained the com- 
plete coding sequence  from an HL60 cDNA library (the 
nucleotide sequence has been deposited in GenBank under 
accession No. L38608). The two cDNA clones exhibit poly- 
morphisms at  three nucleotide positions in the region of 
overlap, two of which result in differences at the protein level 
(G to A from HL60 to the T cell clone at position 836 results 
in the substitution of N231 by S; C to T from HL60 to the 
T cell clone at position 965 results in the substitution of M274 
by T). 
The predicted amino acid sequence of the human homo- 
logue of chicken BEN (ALCAM), a type I membrane pro- 
tein, consists of a 27-amino acid NH2-terminal hydrophobic 
signal peptide, which is cleaved from the mature protein, fol- 
lowed by a 500-amino acid extracellular domain, a 24-amino 
acid hydrophobic transmembrane domain, and a 32-amino 
acid cytoplasmic domain. Glycosylation of ALCAM prob- 
ably accounts for much of the difference between the predicted 
molecular mass of '~65 kD and the 100-105-kD molecular 
mass observed by immunoprecipitation (22, 25), as there are 
nine potential sites for N-linked glycosylation (not shown). 
Based on homology, the extracellular  domain of ALCAM 
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Figure  1.  Binding of COS-CD6  to TE cells is CD6 specific.  (.4) Histograms of CD6 expression on COS-neo (control) and COS-CD6  cells were 
determined by indirect immunofluorescence with the anti-CD6  mAb T12  (11) (solid line) or a control antibody P3 (dotted line). (B) The bar graph 
depicts COS-neo and COS-CD6  binding to TE cells in the presence of either the T12, J4-81,  or P3 mAbs.  The mean and SEM  of three separate 
experiments  are shown. 
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terminal domains are of the V set, and the three Ig domains 
that follow are from the C2 set (33-35). Comparison of the 
amino acid sequence of ALCAM with others in the data base 
showed that it was most homologous to neurolin (37), a pro- 
tein expressed by neural axons of the goldfish visual system 
(38% identity/55% similarity), RAGE (38), a receptor for 
advanced glycation end products (28/43%), and MUC18 (39), 
a cell surface protein whose expression correlates  with the 
metastatic potential of melanoma cells (23/49%) (Fig. 2 A). 
ALCAM Is Expressed by Activated Leukocytes.  By Northern 
blot analysis, an ALCAM cDNA probe hybridized with a 
"~5.2-kb mRNA expressed by mitogen-activated PBMC and 
a number of T  cell, B cell, monocytic, and tumor-derived 
cell lines; activated monocytes showed two additional minor 
species of "~10 and 8.5 kb (Fig. 2 B). ALCAM mRNA was 
Figure 2.  Sequence  analysis of the predicted amino acid sequence of ALCAM, Northern blot analysis of ALCAM mRNA expression, and ALCAM 
cell surface expression by activated T cells. (A) Alignment of the immunoglobulin-like  extracellular domains of ALCAM (residues 35-512), BEN, neu- 
rolin, RAGE, and MUC18. The lowercase letter in front of the protein name designates the species (h, human; c, chicken; f, fish). Consensus residues 
are those shared by three or more proteins. Invariant residues are shaded, and Cys residues are highlighted  with an asterisk. The numbering of the 
peptide sequences shown, obtained from published manuscripts, are as follows: BEN, 8-484 (33); neurolin, 1-466 (37); RAGE, which contains three 
Ig domains, 30-307 (38); MUC18,  40-525 (39). (B) 15/~g of total RNA from adherent peripheral blood monocytes and 25/~g of total RNA from 
resting and PHA-activated (72 h) PBMC, the T cell lymphomas CEM and MOLT4, the erythroleukemia cell line K562, the B cell lymphomas Ramos, 
Raji, and Daudi, the myelomonocytic ceil lines HL60 and U937, the large granular lymphoma YT, the human breast carcinoma HBL-100, and COS 
cells were used to prepare an RNA blot. Random primed 32p-labeled  ALCAM or GAPDH cDNAs were used as probes. (C) PBMC were activated 
in vitro with PHA, and the ability of T cells to bind to either CD6-Rg or J4-81 was monitored for 10 d by two-color immunofluorescence and flow 
cytometry.  The mean channel fluorescence versus day was plotted. 
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ence of  ALCAM transcripts in activated T cells corresponded 
to the expression of a J4-81- and CD6-Rg-binding protein, 
PBMC were activated with PHA, and aliquots of the bulk 
culture were examined by flow cytometry for 10 d. Expres- 
sion of a J4-81- and CD6-binding protein on T  cells was 
observed 2 d after activation, was maximal at 3 d, and declined 
to undetectable  levels 8 d after activation  (Fig. 2 C).  The 
binding ofJ4-81 and CD6-Rg to activated T cells exhibited 
the same expression kinetics, further supporting the hypoth- 
esis that these two molecules recognize the same molecular 
target. 
Assignment  of  Human ALCAM Gene to Chromosome Bands 
3q13.1-q13.2.  FISH  experiments  using  ALCAM  cDNA 
clones as probes localized the gene to a single site on the prox- 
imal long arm of  human chromosome  3. Of the 25 metaphase 
spreads that were analyzed, 20 exhibited  a specific fluores- 
cent signal on both chromatids at  this  site, and 13 out of 
20 had signals on both chromosome 3 homolognes. The chro- 
mosomes were identified by an R-banding pattern produced 
by the incorporation of BrdU after synchronization  of the 
cell culture. The ALCAM signal was assigned to bands 3q13.1- 
q13.2 (Fig. 3). 
This gene localization  is distinct  from that for CD6 on 
chromosome 11 (40). Chromosome 11 also carries the neural 
cell adhesion molecule locus at 11q23.1 encoding the neural 
cell adhesion molecule (41). Of the genes closely related to 
ALCAM,  the gene for the melanoma-associated glycopro- 
tein MUC18 (42) has not been mapped, but another member 
of the Ig superfamily of adhesion molecules, B-CAM, which 
encodes the human F8/G253  antigen, is located on chromo- 
some 19q13.2q-13.3 (43). While these mapping results indi- 
cate that members of this gene family are not all clustered 
in the human genome, one gene for another membrane glyco- 
protein that is also a member of the Ig superfamily (MOX2) 
is located in the vicinity of  ALCAM on human chromosome 
3 band q12-q13 (44, 45). The human ALCAM gene is a poten- 
tial candidate for mutations in Mendelian disorders that affect 
the nervous system and the immune system. No disease sug- 
gestive for further testing has yet been mapped to this region 
of chromosome 3.  The polymorphisms identified  in  the 
ALCAM cDNA will be useful for future candidate gene ex- 
clusion studies. 
ALCAM  is a  CD6  Ligand.  To directly examine if the 
ALCAM cDNA clone isolated from HL60 cells directs the ex- 
pression of  a protein that binds J4-81 and CD6-Rg, the cDNA 
was transfected into COS cells. 3 d after transfection,  the 
COS cells were examined for their ability to bind to J4-81 
(aALCAM) or CD6-Rg by flow cytometry. As shown in Fig. 
4 A, COS cells expressing ALCAM were able to bind to both 
J4-81 and CD6-Rg. To further confirm that ALCAM is a 
CD6 ligand, a chimeric gene encoding ALCAM-Rg was con- 
structed. ALCAM-Rg was expressed  as a covalent homodimer 
with a molecular mass of "~200 kD and was recognized by 
mAb J4-81 (data not shown).  To demonstrate the binding 
of ALCAM-Rg to CD6, COS cells were transfected with 
a cDNA clone encoding CD6 (1) and examined  by flow cytom- 
etry 3 d later. COS cells transfected with CD6 bound both 
G3-6 (aCD6) and ALCAM-Rg (Fig. 4 B). These results dem- 
onstrate that CD6 and ALCAM are a receptor/ligand pair. 
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Figure 3.  Human  chromo- 
somal mapping.  FISH of cDNA 
probes to R-banded chromosomes 
generated  signals on both chro- 
matids (arrows) on chromosome 3 
at bands q13.1-q13.2. The region 
is shown by brackets on a G-band- 
ing ideogram. Figure  4.  Binding  of  AI.CAM to CD6. (A) Flow  cytometry  histograms 
that show the binding of the anti-ALCAM mAb J481 and the CD6-Rg 
fusion protein to COS cell transfectants expressing ALCAM. (/3) Flow 
cytometry  histograms that show the binding of anti-CD6 mAb G3-6 and 
ALCAM-Rg  to COS cell transfectants expressing  CD6. The shaded  histo- 
grams represent level of background binding of mAbs or fusion proteins 
to mock-transfected COS cells. 
Chicken  BEN has been reported  to mediate  homotypic 
adhesion (33-35).  We found that  ALCAM-Rg was indeed 
able to bind COS cells that expressed ALCAM (not shown). 
This  result  supports  previous  observations  of ALCAM- 
ALCAM interactions  and indicates  that  ALCAM mediates 
both  homophilic  and  heterophilic  adhesion. 
The data presented in this report showing that ALCAM- 
CD6 interactions  mediate the adhesion  of CD6-expressing 
cells to TE cells suggest that ALCAM-CD6 binding might 
play a role in regulating T cell maturation.  Other molecules 
including  CD2/LFA-3,  intracellular  adhesion  molecule- 
1/LFA-1, very late antigen-3, -4, -6, and fibronectin can serve 
as  adhesion  molecules  in  thymocyte-stromal  cell  binding 
(46-49). The identification of a CD6 ligand will allow fur- 
ther studies to determine the relative contribution  of CD6 
in thymocyte-TE cell binding and T cell maturation. AI.CAM 
may also be involved in B cell development, since studies in 
the chicken showed that ALCAM (BEN) is expressed on en- 
dothelial cells in the bursa of Fabricius  (50), which is an organ 
in birds where B cells develop. At this time, there is no infor- 
mation on the ability of ALCAM to transduce intracellular 
signals.  The finding that  the anti-CD6  mAb T12 can acti- 
vate T  cells in the presence of accessory cells and in the ap- 
parent absence of cross-linking FcRs suggests that activation 
of T  cells by signaling through CD6 could be important  in 
autoimmune reactivity (11). In support of this, anti-CD6 mAbs 
can enhance or inhibit the autologous MLR (11, 14) (Singer, 
N.  G.,  and D.  A.  Fox,  manuscript  submitted for publica- 
tion).  Since  ALCAM is expressed by activated T  cells  and 
monocytes, as well as by a number of T  and B cell lines,  we 
propose that ALCAM-CD6 interactions play a role in func- 
tional  interactions  between CD6 + T  and B cells  and  acti- 
vated leukocytes, and that ALCAM-ALCAM binding mediates 
adhesive interactions  among  activated leukocytes. 
ALCAM (BEN) in the chicken is expressed predominantly 
during early embryonic development and in the brain (50). 
ALCAM functions as a homophilic adhesion molecule and 
has also been shown to support neurite outgrowth (34, 35). 
We have previously reported  on  the  expression  of human 
M.CAM by neurons in the brain (22). Interactions between 
the immune  and nervous systems may be important  in the 
pathology of certain chronic neurodegenerative diseases such 
as multiple  sclerosis,  Alzheimer's  disease,  and amyotrophic 
lateral  sclerosis (51-53). The finding that ALCAM and CD6 
are both expressed by cells  in these systems may indicate a 
function for this receptor/ligand pair in cellular interactions 
between the immune  and  nervous  systems. 
This  report  describes  the  novel  interaction  between  a 
member of the SRCR family of proteins and a member of 
the Ig supergene family.  This interaction contrasts with the 
finding that CD72 is a ligand for CD5 (54), a protein that 
has weak homology to C-type lectins and suggests that SRCR 
domains are able to interact with members of several different 
protein  families. 
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Note added  in proof: ALCAM is homologous to KG-CAM described in the rat (PeduzziJ.  D., M. H. Irwin, 
and E. E. Geisert, Jr.  1994. Distribution  and Characteristics of a 90-kDa protein,  KG-CAM,  in the rat 
CNS. Brain Res. 640:296-307). 
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